mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of difficult-to-treat partial epilepsy

Neuropharmacology

Volumn 50, Issue 8, 2006, Pages 1006-1015

  Löscher, Wolfgang ^a   Dekundy, Andrzej ^b   Nagel, Jens ^b   Danysz, Wojciech ^b   Parsons, Chris G ^b   Potschka, Heidrun ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Antiepileptic drugs; Epilepsy; Kindling; Metabotropic glutamate receptors

Indexed keywords

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 3 ETHYL 2 METHYLQUINOLIN 6 YL(4 METHOXYCYCLOHEXYL)METHANONE METHANESULFONATE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIAZEPAM; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; VALPROIC ACID;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANXIETY; ARTICLE; BRAIN; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TREATMENT FAILURE; ELECTRIC SHOCK; FEMALE; FOCAL EPILEPSY; GRAND MAL SEIZURE; KINDLING; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; RODENT; SEIZURE;

ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; DIFFERENTIAL THRESHOLD; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; EPILEPSIES, PARTIAL; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; MICRODIALYSIS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; STATISTICS, NONPARAMETRIC; THIAZOLES;

EID: 33646937725     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.02.001     Document Type: Article

References (42)

1. Akbar M.T., Rattray M., Powell J.F., and Meldrum B.S. Altered expression of group I metabotropic glutamate receptors in the hippocampus of amygdala-kindled rats. Brain Res. Mol. Brain Res. 43 (1996) 105-116
2. Al Ghoul W.M., Meeker R.B., and Greenwood R.S. Kindled seizures increase metabotropic glutamate receptor expression and function in the rat supraoptic nucleus. J. Neurosci. Res. 54 (1998) 412-423
3. 3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine). Eur. J. Pharmacol. 473 (2003) 35-40
4. Barton M.E., Klein B.D., Wolf H.H., and White H.S. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 47 (2001) 217-228
5. Barton M.E., Peters S.C., and Shannon H.E. Comparison of the effect of glutamate receptor modulators in the 6 Hz and maximal electroshock seizure models. Epilepsy Res. 56 (2003) 17-26
6. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Perucca E., and Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 61 (2004) 1-48
7. Blümcke I., Becker A.J., Klein C., Scheiwe C., Lie A.A., Beck H., Waha A., Friedl M.G., Kuhn R., Emson P., Elger C., and Wiestler O.D. Temporal lobe epilepsy associated up-regulation of metabotropic glutamate receptors: correlated changes in mGluR1 mRNA and protein expression in experimental animals and human patients. J. Neuropathol. Exp. Neurol. 59 (2000) 1-10
8. Brown W.C., Schiffman D.O., Swinyard E.A., and Goodman L.S. Comparative assay of antiepileptic drugs by "pychomotor" seizure test and minimal electroshock threshold test. J. Pharmacol. Exp. Ther. 107 (1953) 273-283
9. Browne T.R., and Holmes G.L. Epilepsy. N. Engl. J. Med. 344 (2001) 1145-1151
10. Busse C.S., Brodkin J., Tattersall D., Anderson J.J., Warren N., Tehrani L., Bristow L.J., Varney M.A., and Cosford N.D. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1, 3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 29 (2004) 1971-1979
11. Cosford N.D., Tehrani L., Roppe J., Schweiger E., Smith N.D., Anderson J., Bristow L., Brodkin J., Jiang X., McDonald I., Rao S., Washburn M., and Varney M.A. 3-[(2-Methyl-1, 3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J. Med. Chem. 46 (2003) 204-206
12. Doherty J., and Dingledine R. The roles of metabotropic glutamate receptors in seizures and epilepsy. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 251-260
13. Gravius A., Schaefer D., Urbanska E.M., and Danysz W. The diverse effect of mGluR1 and mGluR5 antagonists on learning in three animal models. Soc. Neurosci. Abstr. 30 (2004) 85.14
14. Gravius A., Pietraszek M., Schafer D., Schmidt W.J., and Danysz W. Effects of mGlu1 and mGlu5 receptor antagonists on negatively reinforced learning. Behav. Pharmacol. 16 (2005) 113-121
15. Hönack D., and Löscher W. Kindling increases the sensitivity of rats to adverse effects of certain antiepileptic drugs. Epilepsia 36 (1995) 763-771
16. Kaminski R.M., Livingood M.R., and Rogawski M.A. Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia 45 (2004) 864-867
17. Klodzinska A., Tatarczynska E., Chojnacka-Wojcik E., Nowak G., Cosford N.D., and Pilc A. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling. Neuropharmacology 47 (2004) 342-350
18. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 342 (2000) 314-319
19. 3H]R214127. Neuropharmacology 46 (2004) 609-619
20. Lea P.M., Movsesyan V.A., and Faden A.I. Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors. Br. J Pharmacol. 145 (2005) 527-534
21. Lesage S.S.J., Bischoff F., Van Beijsterveldt L., Meert T., Steckler T., and Ashton D. Novel, centrally active mGluR1 antagonists: in vitro and in vivo pharmacology. Neuropharmacology 43 (2002) 295
22. Litchfield Jr. J.T., and Wilcoxon F. A simplified method of evaluating dose-response experiments. J. Pharmacol. Exp. Ther. 96 (1949) 99-113
23. Löscher W. Animal models of intractable epilepsy. Prog. Neurobiol. 53 (1997) 239-258
24. Löscher W. Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog. Neurobiol. 54 (1998) 721-741
25. Löscher W. New visions in the pharmacology of anticonvulsion. Eur. J. Pharmacol. 342 (1998) 1-13
26. Löscher W., and Rogawski M.A. Epilepsy. In: Lodge D., Danysz W., and Parsons C.G. (Eds). Ionotropic Glutamate Receptors as Therapeutic Target (2002), Graham Publ., Johnson City, TN 91-132
27. Löscher W., and Schmidt D. New horizons in the development of antiepileptic drugs: the search for new targets. Epilepsy Res. 60 (2004) 77-159
28. Meldrum B.S., Akbar M.T., and Chapman A.G. Glutamate receptors and transporters in genetic and acquired models of epilepsy. Epilepsy Res. 36 (1999) 189-204
29. Moldrich R.X., Chapman A.G., De Sarro G., and Meldrum B.S. Glutamate metabotropic receptors as targets for drug therapy in epilepsy. Eur. J. Pharmacol. 476 (2003) 3-16
30. Nagaraja R.Y., Grecksch G., Reymann K.G., Schroeder H., and Becker A. Group I metabotropic glutamate receptors interfere in different ways with pentylenetetrazole seizures, kindling, and kindling-related learning deficits. Naunyn Schmiedebergs Arch. Pharmacol. 370 (2004) 26-34
31. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, Sydney
32. Pietraszek M., Gravius A., Schafer D., Weil T., Trifanova D., and Danysz W. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology 49 (2005) 73-85
33. Pietraszek M., Sukhanov I., Maciejak P., Szyndler J., Gravius A., Wislowska A., Plaznik A., Bespalov A.Y., and Danysz W. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur. J. Pharmacol. 514 (2005) 25-34
34. Racine R.J. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 32 (1972) 281-294
35. Ritzen A., Mathiesen J.M., and Thomsen C. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin. Pharmacol. Toxicol. 97 (2005) 202-213
36. Shannon H.E., Peters S.C., and Kingston A.E. Anticonvulsant effects of LY456236, a selective mGlu1 receptor antagonist. Neuropharmacology 49 Suppl. 1 (2005) 188-195
37. Shipe W.D., Wolkenberg S.E., Williams Jr. D.L., and Lindsley C.W. Recent advances in positive allosteric modulators of metabotropic glutamate receptors. Curr. Opin. Drug Discov. Dev. 8 (2005) 449-457
38. Sperling M.R. The consequences of uncontrolled epilepsy. CNS. Spectr. 9 (2004) 98-99
39. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., and Schoepp D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev. Drug Discov. 4 (2005) 131-144
40. Varty G.B., Grilli M., Forlani A., Fredduzzi S., Grzelak M.E., Guthrie D.H., Hodgson R.A., Lu S.X., Nicolussi E., Pond A.J., Parker E.M., Hunter J.C., Higgins G.A., Reggiani A., and Bertorelli R. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology (Berl) 179 (2005) 207-217
41. White H.S. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 44 Suppl. 7 (2003) 2-8
42. Zhu C.Z., Wilson S.G., Mikusa J.P., Wismer C.T., Gauvin D.M., Lynch III J.J., Wade C.L., Decker M.W., and Honore P. Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur. J. Pharmacol. 506 (2004) 107-118